Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moses Elisaf

Showing results (91-100 of 248) with videos related to

Pageof 25
Sort By:
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|September 26, 2003
Platelets as predictors of vascular risk: is there a practical index of platelet activity?Stavroula Tsiara, Moses Elisaf, I Anita Jagroop, et al.
Hellenic Journal of Cardiology : HJC = Hellenike Kardiologike Epitheorese|August 11, 2006
Beneficial effects of omega-3 fatty acids: the current evidenceIrene Gazi, Evangelos N Liberopoulos, Vasilios G Saougos, et al.
International Journal of Cardiology|April 27, 2017
The CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>-VASc scores predict atrial fibrillation in dyslipidemic individuals: Role of incorporating low high-density lipoprotein cholesterol levelsFotios Barkas, Moses Elisaf, Panagiotis Korantzopoulos, et al.
Angiology|June 17, 2011
Prevalence and risk distribution of residual dyslipidemia in statin-treated patients in GreeceEvangelos Liberopoulos, Fotini Vlasserou, Zoe Mitrogianni, et al.
International Journal of Hypertension|July 13, 2011
Add-on-Statin Extended Release Nicotinic Acid/Laropiprant but Not the Switch to High-Dose Rosuvastatin Lowers Blood Pressure: An Open-Label Randomized StudyAnastazia Kei, Moses Elisaf, Elisavet Moutzouri, et al.
Expert Opinion on Drug Safety|July 28, 2017
Acid-base and electrolyte disorders associated with the use of antidiabetic drugsTheodosios Filippatos, Eleftheria Tzavella, Christos Rizos, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|August 28, 2007
Salicylate-induced proximal tubular dysfunctionVasilis Tsimihodimos, Nikolaos Psychogios, Varvara Kakaidi, et al.
Cardiovascular Therapeutics|March 13, 2014
Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemiaAnastazia Kei, Constantinos Tellis, Evangelos Liberopoulos, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|April 30, 2005
Disturbances of phosphate metabolism: another feature of metabolic syndromeRigas Kalaitzidis, Vasilis Tsimihodimos, Eleni Bairaktari, et al.
Atherosclerosis|June 13, 2003
Non-high density lipoprotein cholesterol and coronary events during long-term statin treatmentVasilios G Athyros, Athanasios A Papageorgiou, Athanasios N Symeonidis, et al.
Pageof 25

Showing results (91-100 of 248) with videos related to

Sort By:
Pageof 25
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|September 26, 2003
Platelets as predictors of vascular risk: is there a practical index of platelet activity?Stavroula Tsiara, Moses Elisaf, I Anita Jagroop, et al.
Hellenic Journal of Cardiology : HJC = Hellenike Kardiologike Epitheorese|August 11, 2006
Beneficial effects of omega-3 fatty acids: the current evidenceIrene Gazi, Evangelos N Liberopoulos, Vasilios G Saougos, et al.
International Journal of Cardiology|April 27, 2017
The CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>-VASc scores predict atrial fibrillation in dyslipidemic individuals: Role of incorporating low high-density lipoprotein cholesterol levelsFotios Barkas, Moses Elisaf, Panagiotis Korantzopoulos, et al.
Angiology|June 17, 2011
Prevalence and risk distribution of residual dyslipidemia in statin-treated patients in GreeceEvangelos Liberopoulos, Fotini Vlasserou, Zoe Mitrogianni, et al.
International Journal of Hypertension|July 13, 2011
Add-on-Statin Extended Release Nicotinic Acid/Laropiprant but Not the Switch to High-Dose Rosuvastatin Lowers Blood Pressure: An Open-Label Randomized StudyAnastazia Kei, Moses Elisaf, Elisavet Moutzouri, et al.
Expert Opinion on Drug Safety|July 28, 2017
Acid-base and electrolyte disorders associated with the use of antidiabetic drugsTheodosios Filippatos, Eleftheria Tzavella, Christos Rizos, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|August 28, 2007
Salicylate-induced proximal tubular dysfunctionVasilis Tsimihodimos, Nikolaos Psychogios, Varvara Kakaidi, et al.
Cardiovascular Therapeutics|March 13, 2014
Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemiaAnastazia Kei, Constantinos Tellis, Evangelos Liberopoulos, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|April 30, 2005
Disturbances of phosphate metabolism: another feature of metabolic syndromeRigas Kalaitzidis, Vasilis Tsimihodimos, Eleni Bairaktari, et al.
Atherosclerosis|June 13, 2003
Non-high density lipoprotein cholesterol and coronary events during long-term statin treatmentVasilios G Athyros, Athanasios A Papageorgiou, Athanasios N Symeonidis, et al.
Pageof 25